Search

Your search keyword '"Ribakovsky, Elena"' showing total 38 results
Start Over Author "Ribakovsky, Elena"
38 results on '"Ribakovsky, Elena"'

1. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

8. Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL

Author

Benjamini, Ohad, primary, Gershon, Rotem, additional, Bar‐Haim, Erez, additional, Lustig, Yaniv, additional, Cohen, Hila, additional, Doolman, Ram, additional, Kedmi, Meirav, additional, Ribakovsky, Elena, additional, Kneller, Abraham, additional, Hod, Tammy, additional, Erez, Noam, additional, Levy, Itzhak, additional, Rahav, Galia, additional, and Avigdor, Abraham, additional

Published
2022
Full Text
View/download PDF

9. Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL.

Author

Benjamini, Ohad, Gershon, Rotem, Bar‐Haim, Erez, Lustig, Yaniv, Cohen, Hila, Doolman, Ram, Kedmi, Meirav, Ribakovsky, Elena, Kneller, Abraham, Hod, Tammy, Erez, Noam, Levy, Itzhak, Rahav, Galia, and Avigdor, Abraham

Subjects
COVID-19 vaccines, HUMORAL immunity, CHRONIC lymphocytic leukemia, COVID-19, INTERFERON gamma, ANTIBODY titer
Abstract

We assessed the humoral and cellular response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL. A total of 67 patients with CLL and 85 age matched controls tested for serologic response and pseudo‐neutralization assay. We also tested the functional T‐cell response by interferon gamma (IFNγ) to spike protein in 26 patients. Two weeks after the fourth vaccine antibody serologic response was evident in 37 (55.2%) patients with CLL, 20 /22 (91%) of treatment naïve, and 9/32 (28%) patients with ongoing therapy, compared with 100% serologic response in age matched controls. The antibody titer increased by 10‐fold in patients with CLL, however, still 88‐folds lower than age matched controls. Predictors of better chances of post fourth vaccination serologic response were previous positive serologies after second, third, and pre‐fourth vaccination, neutralizing assay, and treatment naïve patients. T‐cell response improved from 42.3% before the fourth vaccine to 84.6% 2 weeks afterwards. During the time period of 3 months after the fourth vaccination, 14 patients (21%) developed COVID‐19 infection, all recovered uneventfully. Our data demonstrate that fourth SARS‐CoV‐2 vaccination improves serologic response in patients with CLL to a lesser extent than healthy controls and induces functional T‐cell response. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Supplement to: Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

Author

Palumbo, Antonio, Cavallo, Federica, Gay, Francesca, Di Raimondo, Francesco, Ben Yehuda, Dina, Petrucci, Maria Teresa, Pezzatti, Sara, Caravita, Tommaso, Cerrato, Chiara, Ribakovsky, Elena, Genuardi, Mariella, Cafro, Anna, Marcatti, Magda, Catalano, Lucio, Offidani, Massimo, Carella, Angelo Michele, Zamagni, Elena, Patriarca, Francesca, Musto, Pellegrino, Evangelista, Andrea, Ciccone, Giovannino, Omedé, Paola, Crippa, Claudia, Corradini, Paolo, Nagler, Arnon, Boccadoro, Mario, and Cavo, Michele

Published
2014

11. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

Author

Palumbo, Antonio, Cavallo, Federica, Gay, Francesca, Di Raimondo, Francesco, Ben Yehuda, Dina, Petrucci, Maria Teresa, Pezzatti, Sara, Caravita, Tommaso, Cerrato, Chiara, Ribakovsky, Elena, Genuardi, Mariella, Cafro, Anna, Marcatti, Magda, Catalano, Lucio, Offidani, Massimo, Carella, Angelo Michele, Zamagni, Elena, Patriarca, Francesca, Musto, Pellegrino, Evangelista, Andrea, Ciccone, Giovannino, Omedé, Paola, Crippa, Claudia, Corradini, Paolo, Nagler, Arnon, Boccadoro, Mario, and Cavo, Michele

Published
2014
Full Text
View/download PDF

14. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Goldhecht, Yair, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit, additional, Horwitz, Netanel, additional, Gutwein, Odit, additional, Gurion, Ronit, additional, Itchaki, Gilad, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Zektser, Miri, additional, Tadmor, Tamar, additional, Dally, Nagib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2020
Full Text
View/download PDF

17. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit Ringelstein, additional, Gutwein, Odit, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Dally, Najib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

19. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

Author

Segman, Yafit, Ribakovsky, Elena, Avigdor, Abraham, Goldhecht, Yair, Vainstein, Vladimir, Goldschmidt, Neta, Harlev, Shimrit, Horwitz, Netanel, Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Zektser, Miri, Tadmor, Tamar, Dally, Nagib, Filanovsky, Kalman, Leiba, Merav, and Sarid, Nadav

Subjects
*DIFFUSE large B-cell lymphomas, *PROGRESSION-free survival, *LYMPHOMAS, *HODGKIN'S disease
Abstract

The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.

Author

Shimony, Shai, Horowitz, Netanel, Ribakovsky, Elena, Rozovski, Uri, Avigdor, Abraham, Zloto, Keren, Berger, Tamar, Avivi, Irit, Perry, Chava, Abadi, Uri, Raanani, Pia, Gafter‐Gvili, Anat, Gurion, Ronit, and Gafter-Gvili, Anat

Subjects
CUTANEOUS T-cell lymphoma, T-cell lymphoma, HISTONE deacetylase, ENZYME inhibitors, CANCER treatment, ANTINEOPLASTIC antibiotics, COMPARATIVE studies, DRUG resistance in cancer cells, MEDICAL cooperation, PEPTIDES, PROGNOSIS, REOPERATION, RESEARCH, SKIN diseases, DISEASE relapse, EVALUATION research, TREATMENT effectiveness, KAPLAN-Meier estimator
Abstract

Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), treated with at least one prior systemic therapy. Currently, there is paucity of real-life data on the efficacy and safety of romidepsin in R/R T-cell lymphoma. This national, multicenter study presents real-life data on the efficacy and safety of romidepsin in R/R T-cell lymphoma. Patients diagnosed and treated with romidepsin for R/R CTCL or PTCL between 2013 and 2018 were retrospectively reviewed. Outcomes included overall survival (OS), event-free survival (EFS), overall response rate (ORR), complete response (CR), and adverse events. Fifty-three patients with R/R PTCL (n = 42) or CTCL (n = 11) were included. Among CTCL patients, median OS was not reached, ORR was 25%, and none achieved CR. Among PTCL patients, median OS was 7.1 months, EFS was 1.9 months, ORR rate was 33%, and 12.5% achieved CR. In a univariate analysis, predictors for longer EFS include any response to therapy, number of previous lines, and PTCL subclass (with better results for angioimmunobalstic T-cell lymphoma). In a univariate and multivariate analysis for OS, treatment response was the only factor predicting OS (OR 4.48; CI 95%, 1.57-12.79; P = .005). Most grade 3 and 4 adverse events were hematological (35%). Infections were reported in 34% of patients. This real-life experience with romidepsin confirms the results of the pivotal phase II trials. PTCL subtype and the number of previous lines of therapy have an impact on EFS. In addition, patients who had good response to romidepsin benefited most in terms of both EFS and OS. Efforts should be done to identify those patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

21. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway

Author

Beider, Katia, primary, Rosenberg, Evgenia, additional, Bitner, Hanna, additional, Shimoni, Avichai, additional, Leiba, Merav, additional, Koren-Michowitz, Maya, additional, Ribakovsky, Elena, additional, Klein, Shiri, additional, Olam, Devorah, additional, Weiss, Lola, additional, Wald, Hanna, additional, Abraham, Michal, additional, Galun, Eithan, additional, Peled, Amnon, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

22. Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Author

Benjamini, Ohad, primary, Zlotnick, Maya, additional, Ribakovsky, Elena, additional, Kedmi, Meirav, additional, Duek, Adrian, additional, Merkel, Drorit, additional, Leiba, Merav, additional, Danylesko, Ivetta, additional, Shem-Tov, Noga, additional, Yerushalmi, Ronit, additional, Shimoni, Avichai, additional, Avigdor, Abraham, additional, Nagler, Arnon, additional, and Volchek, Yulia, additional

Published
2016
Full Text
View/download PDF

23. Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects

Author

Simon, Amos J., primary, Lev, Atar, additional, Zhang, Yong, additional, Weiss, Batia, additional, Rylova, Anna, additional, Eyal, Eran, additional, Kol, Nitzan, additional, Barel, Ortal, additional, Cesarkas, Keren, additional, Soudack, Michalle, additional, Greenberg-Kushnir, Noa, additional, Rhodes, Michele, additional, Wiest, David L., additional, Schiby, Ginette, additional, Barshack, Iris, additional, Katz, Shulamit, additional, Pras, Elon, additional, Poran, Hana, additional, Reznik-Wolf, Haike, additional, Ribakovsky, Elena, additional, Simon, Carlos, additional, Hazou, Wadi, additional, Sidi, Yechezkel, additional, Lahad, Avishay, additional, Katzir, Hagar, additional, Sagie, Shira, additional, Aqeilan, Haifa A., additional, Glousker, Galina, additional, Amariglio, Ninette, additional, Tzfati, Yehuda, additional, Selig, Sara, additional, Rechavi, Gideon, additional, and Somech, Raz, additional

Published
2016
Full Text
View/download PDF

25. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study

Author

Gafter-Gvili, Anat, primary, Ribakovsky, Elena, additional, Mizrahi, Nadav, additional, Avigdor, Abraham, additional, Aviv, Ariel, additional, Vidal, Liat, additional, Ram, Ron, additional, Perry, Chava, additional, Avivi, Irit, additional, Kedmi, Meirav, additional, Nagler, Arnon, additional, Raanani, Pia, additional, and Gurion, Ronit, additional

Published
2015
Full Text
View/download PDF

31. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.

Author

Gafter-Gvili, Anat, Ribakovsky, Elena, Mizrahi, Nadav, Avigdor, Abraham, Aviv, Ariel, Vidal, Liat, Ram, Ron, Perry, Chava, Avivi, Irit, Kedmi, Meirav, Nagler, Arnon, Raanani, Pia, and Gurion, Ronit

Subjects
*LYMPHOPROLIFERATIVE disorders, *BACTERIAL diseases, *HEMATOLOGY, *PROPORTIONAL hazards models, *DISEASE incidence, *RETROSPECTIVE studies
Abstract

A multi-center retrospective analysis of a cohort of patients in Israel treated with any bendamustine containing regimen between 2010-2014 was performed in order to determine the incidence and predictors for infection. The Kaplan Meier Model, employing log rank analysis, was used to assess time-to-infection. The Cox Proportional Hazards model was used to analyze multivariate effects of risk and 234 patients were included in the analysis. One hundred and nine (46.6%) developed at least one infection and 33.76% had severe infections. Seventy-six (41.5%) developed bacterial infection, nine (3.8%) fungal infection and 26 (11.5%) had viral infections. Factors significantly associated with time to infection on multivariable analysis were: bendamustine-combinations [hazard ratio (HR) = 0.589 (95% CI = 0.374-0.926), p = 0.022], Hb level [HR = 0.791 (95% CI = 0.716-0.875), p < 0.0001] and ischemic heart disease [HR = 1.828 (95% CI = 1.165-2.868), p = 0.009]. Infections were associated with a higher mortality and hospitalization rate. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results